Shahrokh Shariat, Professor and Chairman of the Department of Urology, Director of the Comprehensive Cancer Center, Co-lead of the Austrian Comprehensive Cancer Network, Medical University of Vienna, Vienna General Hospital, Vienna, AUT shared a post on LinkedIn:
“Excited to share our new JAMA Network Open systematic review and meta-analysis on time-of-day immunotherapy administration in advanced cancers.
Across 29 studies including 6,129 patients, earlier immune checkpoint inhibitor administration was associated with improved overall and progression-free survival. These findings highlight the potential clinical relevance of chronotherapy and call for prospective validation before implementation in routine care.”
Title: Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis
Authors: Shota Inoue, Ichiro Tsuboi, Marcin Miszczyk, Keiichiro Miyajima, Navid Roessler, Ahmed R. Alfarhan, Satoshi Katayama, Pierre I. Karakiewicz, Motoo Araki, Shahrokh F. Shariat
Read The Full Article
Other articles about Immunotherapy on OncoDaily.